Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
AUSTRALIA's Mitchell Starc believes Sunday's (19) World Cup final against India at Ahmedabad's 130,000-capacity stadium will be "loud and a spectacle of cricket".
Five-time champions Australia edged out South Africa by three wickets in a tense chase of 213 in Kolkata on Thursday (16) to make their eighth World Cup final.
"It's a big occasion, it's a World Cup final," Starc, who returned figures of 3-34 to help bowl out South Africa for 212, told reporters.
"Guys in both changing rooms have been there before at different formats. Both teams played each other in the (World Test Championship) Final earlier in the year. I don't think either changing room is new to big occasions.
"It's going to be loud. No doubt there's going to be different amounts of pressure at different times on both teams. I think it's just going to be a great spectacle of cricket."
Rohit Sharma's India have a perfect 10 wins from 10 games at this World Cup after seeing off New Zealand by 70 runs in the first semi-final on Wednesday (15).
They are firm favourites to lift the trophy for a third time and second at home after 2011.
"They've been the best in the tournament so far and we both find ourselves in the finals," said Starc of the match-up.
"That's what World Cups are about. We played them in our first game of the tournament, now we get to take them on in the last. What a place to be at the end of a World Cup."
Australia started the tournament with losses to India and then South Africa before they won seven straight league matches to storm into the final-four.
Against India, they lost by six wickets in Chennai after being bowled out for 199, and then slumped to a 134-run defeat to the Proteas in Lucknow.
Australia last won the World Cup in 2015 but kept adding to their trophy cabinet after they clinched the T20 World Cup in 2021.
They were crowned Test champions in June this year when they defeated India by 209 runs at The Oval.
Australian batsmen had a tough day in Kolkata after they slipped to 137-5 following a 62 by Travis Head, whose departure triggered a collapse as South African spinners Keshav Maharaj and Tabraiz Shamsi attempted to take control.
But Steve Smith (30), Josh Linglis (28), Starc (16 not out) and Pat Cummins (14 not out) guided the team home with 16 balls to spare.
On Sunday, Indian spinners Kuldeep Yadav and Ravindra Jadeja will be a threat to the Australian batsmen in Ahmedabad.
"I guess we'll find out when we get to Ahmedabad tomorrow and see if it's a fresh wicket or an old wicket," Starc said tongue-in-cheek after reports accused India of switching pitches for their semi-final win over New Zealand in Mumbai on Wednesday.
Despite the anticipation ahead of Sunday's final after six weeks of action across India, not everybody is excited.
"To be honest, there's about a 1 per cent chance I'll be watching. And to be even more brutally honest, I actually don't care," said South Africa coach Rob Walter.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.